What is she best known for?
The fields of study she is best known for:
- Cancer
- Gene
- Internal medicine
Her scientific interests lie mostly in Cancer, microRNA, Bioinformatics, Non-coding RNA and Cancer research.
Her Cancer research is multidisciplinary, incorporating elements of Gene, Drug resistance and Pathology.
Ioana Berindan-Neagoe interconnects Colorectal cancer, Metastasis, Computational biology and Molecular oncology in the investigation of issues within microRNA.
The concepts of her Bioinformatics study are interwoven with issues in Hepatocellular cancer, Whole genome microarray, Functional studies, Regulatory circuit and Mir 17 5p.
Her Non-coding RNA study incorporates themes from Carcinogenesis, Hormone, Signal transduction and Carcinogen.
Her studies deal with areas such as Lung cancer, Chemotherapy, Doxorubicin and Immunology as well as Cancer research.
Her most cited work include:
- CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer (388 citations)
- MicroRNAome genome: a treasure for cancer diagnosis and therapy. (303 citations)
- Junk DNA and the long non-coding RNA twist in cancer genetics. (208 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Cancer, Cancer research, microRNA, Internal medicine and Oncology.
Her studies in Cancer integrate themes in fields like Lung cancer, Disease and Immunology.
The various areas that Ioana Berindan-Neagoe examines in her Cancer research study include Apoptosis, Breast cancer, Triple-negative breast cancer and Metastasis.
She works mostly in the field of microRNA, limiting it down to concerns involving Bioinformatics and, occasionally, Malignancy.
Much of her study explores Internal medicine relationship to Stem cell.
Her research links Pathological with Oncology.
She most often published in these fields:
- Cancer (34.10%)
- Cancer research (30.49%)
- microRNA (28.20%)
What were the highlights of her more recent work (between 2019-2021)?
- Cancer research (30.49%)
- microRNA (28.20%)
- Cancer (34.10%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Cancer research, microRNA, Cancer, Cancer cell and Computational biology.
Ioana Berindan-Neagoe has researched Cancer research in several fields, including Downregulation and upregulation, Gene, Breast cancer, Triple-negative breast cancer and Drug resistance.
Her microRNA research includes themes of Gene expression, Oncology, Carcinogenesis, Disease and Colorectal cancer.
In general Cancer study, her work on Tumor microenvironment often relates to the realm of Context, thereby connecting several areas of interest.
Her Cancer cell research incorporates themes from Phenotype, Metastasis, RNA and Cell biology.
Her research in Metastasis tackles topics such as Gene knockdown which are related to areas like Small nucleolar RNA and Long non-coding RNA.
Between 2019 and 2021, her most popular works were:
- The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches (30 citations)
- A Comprehensive Picture of Extracellular Vesicles and Their Contents. Molecular Transfer to Cancer Cells. (21 citations)
- Nanoscale delivery systems for microRNAs in cancer therapy. (21 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Cancer research, Cancer, microRNA, Metastasis and Microvesicles are her primary areas of study.
Her Cancer research study combines topics from a wide range of disciplines, such as Cell migration, Cell growth, Downregulation and upregulation, Breast cancer and Colorectal cancer.
Ioana Berindan-Neagoe mostly deals with Tumor microenvironment in her studies of Cancer.
The study incorporates disciplines such as RNA, Computational biology and Bioinformatics in addition to microRNA.
Her study in Metastasis is interdisciplinary in nature, drawing from both Cancer cell and Gene knockdown.
Her research integrates issues of Tumor progression, Cancer therapy and Angiogenesis in her study of Microvesicles.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
